Interleukin-6-634G>C genetic polymorphism is associated with prognosis following surgery for advanced thoracic esophageal squamous cell carcinoma

Digestive Surgery

Volumn 29, Issue 3, 2012, Pages 194-201

  Motoyama, Satoru ^a   Nakatsu, Toshinobu ^a   Miura, Masatomo ^b   Hinai, Yudai ^b   Minamiya, Yoshihiro ^a   Ogawa, Jun Ichi ^a  

^a AKITA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b AKITA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Cancer prognosis; Esophagectomy; Interleukin 6 polymorphism; Interleukin 6 receptor polymorphism; Thoracic esophageal squamous cell carcinoma

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BLOOD; ESOPHAGUS RESECTION; ESOPHAGUS TUMOR; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; GENOTYPE; HUMANS; INTERLEUKIN-6; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMORPHISM, GENETIC; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, INTERLEUKIN-6; SURVIVAL RATE;

EID: 84861819712     PISSN: 02534886     EISSN: None     Source Type: Journal    
DOI: 10.1159/000336952     Document Type: Article

References (26)

1. Grivennikov S, Karin M: Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell 2008;13:7-9.
2. Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A, Burg J, Strand S, Kiesslich R, Huber S, Ito H, Nishimoto N, Yoshizaki K, Kishimoto T, Galle PR, Blessing M, Rose-John S, Neurath MF: TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004;21:491-501.
3. Cardillo MR, Ippoliti F: Interleukin-6, inter-leukin-10 and heat shock protein-90 expression in renal epithelial neoplasias and surrounding normal-appearing renal parenchyma. Int J Immunopathol Pharmacol 2007;20:37-46.
4. George DJ, Halabi S, Shepard TF, Vogelzang NJ, Hayes DF, Small EJ, Kantoff PW; Cancer and Leukemia Group B 9480: Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001;7:1932-1936.
5. Sasser AK, Sullivan NJ, Studebaker AW, Hendey LF, Axel AE, Hall BM: Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer. FASEB J 2007;21: 3763-3770.
6. Mouawad R, Rixe O, Meric JB, Khayat D, Soubrane C: Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study. Cytokines Cell Mol Ther 2002;7:151-156.
7. Ng T, Vezeridis MP: Advances in the surgical treatment of esophageal cancer. J Surg Oncol 2010;101: 725-729.
8. Oka M, Yamamoto K, Takahashi M, Hako-zaki M, Abe T, Iizuka N: Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res 1996; 56: 2776-2780.
9. Lagmay JP, London WB, Gross TG, Ter-muhlen A, Sullivan N, Axel A, Mundy B, Ra-nalli M, Canner J, McGrady P, Hall B: Prognostic significance of interleukin-6 single nucleotide polymorphism genotypes in neuroblastoma: rs1800795 (promoter) and rs8192284 (receptor). Clin Cancer Res 2009; 15:5234-5239.
10. DeMichele A, Martin AM, Mick R, Gor P, Wray L, Klein-Cabral M, Athanasiadis G, Colligan T, Stadtmauer E, Weber B: Interleu-kin-6 -174G-1C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res 2003; 63:80518056.
11. Snoussi K, Strosberg AD, Bouaouina N, Ben Ahmed S, Chouchane L: Genetic variation in pro-inflammatory cytokines (interleukin- 1beta, interleukin-1alpha and interleukin-6) associated with the aggressive forms, survival, and relapse prediction of breast carcinoma. Eur Cytokine Netw 2005; 16: 253-260.
12. Buraczynska M, Jozwiak L, Ksiazek P, Boro-wicz E, Mierzicki P: Interleukin-6 gene polymorphism and faster progression to end-stage renal failure in chronic glomerulonephritis. Transl Res 2007;150:101-105.
13. Wolford JK, Colligan PB, Gruber JD, Bogardus C: Variants in the interleukin 6 receptor gene are associated with obesity in Pima Indians. Mol Genet Metab 2003;80:338-343.
14. Nakatsu T, Motoyama S, Maruyama K, Usami S, Sato Y, Miura M, Hinai Y, Saito H, Min-amiya Y, Murata K, Ogawa J: Tumoral CRP expression in thoracic esophageal squamous cell cancers is associated with poor outcomes. Surg Today, in press.
15. Hong DS, Angelo LS, Kurzrock R: Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer 2007; 110:1911-1928.
16. Belluco C, Nitti D, Frantz M, Toppan P, Basso D, Plebani M, Lise M, Jessup JM: Interleu-kin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. Ann Surg Oncol 2000; 7: 133-138.
17. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P: The effect of novel polymorphisms in the inter-leukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102:1369-1376.
18. Walston JD, Fallin MD, Cushman M, Lange L, Psaty B, Jenny N, Browner W, Tracy R, Durda P, Reiner A: IL-6 gene variation is as- sociated with IL-6 and C-reactive protein levels but not cardiovascular outcomes in the Cardiovascular Health Study. Hum Genet 2007;122:485-494.
19. Nakajima T, Ota N, Yoshida H, Watanabe S, Suzuki T, Emi M: Allelic variants in the interleukin-6 gene and essential hypertension in Japanese women. Genes Immun 1999; 1: 115-119.
20. Kitamura A, Hasegawa G, Obayashi H, Ka-miuchi K, Ishii M, Yano M, Tanaka T, Yama-guchi M, Shigeta H, Ogata M, Nakamura N, Yoshikawa T: Interleukin-6 polymorphism (-634C/G) in the promotor region and the progression of diabetic nephropathy in type 2 diabetes. Diabet Med 2002;19:1000-1005.
21. Esfandi F, Mohammadzadeh Ghobadloo S, Basati G: Interleukin-6 level in patients with colorectal cancer. Cancer Lett 2006; 244:7678.
22. Zhang GJ, Adachi I: Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res 1999; 19: 1427-1432.
23. Huang SP, Wu MS, Shun CT, Wang HP, Lin MT, Kuo ML, Lin JT: Interleukin-6 increases vascular endothelial growth factor and an-giogenesis in gastric carcinoma. J Biomed Sci 2004;11:517-527.
24. Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M, Ceccarelli C, Santini D, Paterini P, Marcu KB, Chieco P, Bonafe M: IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 2007; 117: 3988-4002.
25. Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B, Bromberg JF: Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 2007;117: 3846-3856.
26. Conze D, Weiss L, Regen PS, Bhushan A, Weaver D, Johnson P, Rincon M: Autocrine production of interleukin 6 causes multi-drug resistance in breast cancer cells. Cancer Res 2001;61: 8851-8858.